"Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.

[This corrects the article on p. 32 in vol. 25, PMID: 29507481.]. Click to show full abstract

[This corrects the article on p. 32 in vol. 25, PMID: 29507481.].

Keywords: advanced neuroendocrine; everolimus treatment; treatment advanced; effectiveness everolimus; erratum cost; cost effectiveness

Journal Title: Current oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended